iTeos Therapeutics (NASDAQ:ITOS) Earns Buy Rating from HC Wainwright

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $21.00 price objective on the stock. HC Wainwright's price objective would indicate a potential upside of 173.44% from the company's previous close.

Separately, Wedbush reaffirmed an "outperform" rating and issued a $25.00 price target on shares of iTeos Therapeutics in a research note on Thursday.

iTeos Therapeutics Stock Performance

Shares of NASDAQ ITOS traded down $0.27 during trading hours on Friday, hitting $7.68. The company's stock had a trading volume of 658,406 shares, compared to its average volume of 445,015. The business has a 50-day simple moving average of $8.79 and a 200-day simple moving average of $13.05. The stock has a market cap of $280.58 million, a price-to-earnings ratio of -2.52 and a beta of 1.37. iTeos Therapeutics has a 12 month low of $7.44 and a 12 month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.18) by $0.13. On average, equities research analysts forecast that iTeos Therapeutics will post -3.46 EPS for the current year.

Insider Transactions at iTeos Therapeutics

In other news, CFO Matthew Gall bought 5,000 shares of the firm's stock in a transaction on Tuesday, November 19th. The stock was acquired at an average cost of $7.73 per share, with a total value of $38,650.00. Following the completion of the acquisition, the chief financial officer now owns 65,429 shares of the company's stock, valued at approximately $505,766.17. This represents a 8.27 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 12.50% of the company's stock.

Institutional Investors Weigh In On iTeos Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company boosted its stake in iTeos Therapeutics by 6.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company's stock valued at $164,000 after purchasing an additional 690 shares during the last quarter. Creative Planning boosted its position in shares of iTeos Therapeutics by 6.5% during the third quarter. Creative Planning now owns 19,636 shares of the company's stock valued at $200,000 after buying an additional 1,196 shares during the last quarter. nVerses Capital LLC increased its holdings in iTeos Therapeutics by 212.5% in the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company's stock worth $26,000 after buying an additional 1,700 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in iTeos Therapeutics by 60.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company's stock worth $72,000 after buying an additional 2,646 shares during the last quarter. Finally, Point72 DIFC Ltd bought a new position in iTeos Therapeutics during the 3rd quarter valued at about $31,000. Institutional investors own 97.16% of the company's stock.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.